Document › Details

Roche. (1/15/10). "Press Release: Enhanced Emergency Diagnosis of Heart Failure". Rotkreuz.

Region Region ww excl US
Organisation Organisation Roche (Group)
Products Product BNP (B-type Natriuretic Peptide) (marker)
  Product 2 COBAS® h 232 system
Index terms Index term launch (product/service)
  Index term 2 heart failure
     
Roche today announced a measuring range extension for its Roche CARDIAC proBNP point-of-care test for suspected acute heart failure. An extended measuring range not only helps to identify heart failure patients, but also delivers valuable information on the severity of the disease on the spot. The improved version of the test will run on the cobas h 232 POC system*, Roche's portable solution in emergency rooms and increasingly in pre-hospital emergency settings.

Outside the hospital diagnostic options in emergency medicine are limited, but to save a life, decisions have to be made quickly. In these extremely challenging situations ambulance services are very often confronted with unclear chest pain and shortness of breath in their patients. However, obtaining a secure diagnosis on the spot is problematic, because the mentioned symptoms are non-specific and can be caused by a wide range of conditions such as acute heart failure, myocardial infarction or pulmonary embolism. Point of care blood testing, performed next to the patient with a portable diagnostic device can help to identify the problem, enabling care givers to initiate treatment earlier and direct patients to the appropriate hospital or unit within the hospital for further diagnostic and therapeutic measures.

The newly launched version of the Roche test for heart failure will be marketed under the name Roche CARDIAC proBNP+ and is the latest in a range of cardiovascular point-of-care tests on the cobas h 232 POC system. Other state-of-the-art diagnostic emergency tests on the same platform are D-dimer for the exclusion of pulmonary embolism and cardiac troponin T, which supports the pre-hospital diagnosis of myocardial infarction (MI) in patients who do not present the typical electrocardiogram (ECG) changes.

About cobas h 232 POC system*

The portable cobas h 232 POC system enables and supports quick diagnostic decisions with key cardiac parameters available at the point of care. The system is easy to use at the patient's site, even by non laboratorians. After the sample absorption onto the strip the instrument can be moved during the measurement. Results are displayed in less than 15 minutes.

All tests on the system (myoglobin, troponin T, CK-MB, NT-proBNP, D-dimer) are standardized against laboratory platforms and clinically validated.

Please find a high resolution image (300 dpi) of the cobas h 232 POC system here
[http://www.roche.com/pages/photo_library/images/jpeg/0100238.jpg]

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalised healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2008, Roche had over 80,000 employees worldwide and invested almost 9 billion Swiss francs in R&D. The Group posted sales of 45.6 billion Swiss francs. Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.

All trademarks used or mentioned in this release are protected by law.

*the cobas h 232 POC system and the test assays for this platform are not available in the US.

   
Record changed: 2010-07-21

More documents for Roche (Group)

To get even more information, please take a look at our [gs] professional services offering and read the gene-sensor Product Flyer [PDF file]
» top